Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Psychiatry Res Neuroimaging. 2017 Jul 30;265:98-101. doi: 10.1016/j.pscychresns.2016.10.011. Epub 2016 Nov 5.

Correlation of florbetaben PET imaging and the amyloid peptide Aß42 in cerebrospinal fluid.

Author information

1
Charité-Universitätsmedizin Berlin, Experimental and Clinical Research Center - ECRC, Berlin, Germany; Charité-Universitätsmedizin Berlin, Institute of Neuropathology, Berlin, Germany. Electronic address: carola.schipke@charite.de.
2
Piramal Imaging GmbH, Berlin, Germany.
3
Department of Psychiatry, Charité-Campus Benjamin Franklin, Berlin, Germany.
4
Charité-Universitätsmedizin Berlin, Experimental and Clinical Research Center - ECRC, Berlin, Germany; Department of Psychiatry, Charité-Campus Benjamin Franklin, Berlin, Germany.
5
Molecular NeuroImaging, LLC (MNI), New Haven, CT, USA.
6
Leipzig University, Department of Nuclear Medicine, Leipzig, Germany.

Abstract

Today, the use of biomarkers such as amyloid-specific positron emission tomography (PET) tracers and information derived from cerebrospinal fluid (CSF) can support the diagnosis of Alzheimer's disease (AD) as an indicator for the presence of amyloid pathology. We here show that the PET signal of the 18F-labelled tracer florbetaben (NeuraCeq™), that binds to amyloid-beta plaques, inversely correlates with CSF levels of Aß42, another biomarker for AD. Results from the two biomarkers were concordant in 35 out of 38 subjects. In 7 AD subjects (20%) at least one biomarker was inconsistent with the clinical diagnosis. This confirms known limitations of the clinical AD diagnosis and highlights the potential of biomarker-assisted diagnosis to improve accuracy.

KEYWORDS:

Alzheimer's disease; Beta-amyloid; Biomarker; Cerebrospinal fluid; Florbetaben; PET-tracer

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center